

Online Resource 1. European Organization for Research and Treatment of Cancer Quality of Life C30 subscales throughout taxane therapy. Significant detrimental changes in select subscales were associated with taxane therapy. Means \pm SD (p-value for contrast with timepoint 1)

| Patient-Reported Outcome | Timepoint 1 | Timepoint 2 | Timepoint 3 | Timepoint 4 | Timepoint 5 |
|---|-----------------|-------------------------|-------------------------|-------------------------|-------------------------|
| EORTC QLQ-C30 Functional Subscales | | | | | |
| Patients Assessed (n) | 29 | 27 | 27 | 27 | 28 |
| Global Health/ QOL | 76.8 \pm 16.6 | 70.9 \pm 23.4 (0.1) | 76.3 \pm 15.4 (0.9) | 76.1 \pm 13.9 (0.8) | 80.9 \pm 14.9 (0.3) |
| Physical Functioning | 96.5 \pm 7.0 | 91.8 \pm 10.1 (0.02)* | 90.6 \pm 12.4 (0.02)* | 91.7 \pm 12.1 (0.02)* | 89.9 \pm 16.0 (0.04)* |
| Role Functioning | 86.4 \pm 23.5 | 86.7 \pm 23.6 (0.9) | 87.9 \pm 21.3 (0.6) | 89.4 \pm 13.3 (0.5) | 83.5 \pm 27.2 (0.5) |
| Emotional Functioning | 80.4 \pm 20.7 | 81.9 \pm 22.8 (0.7) | 79.6 \pm 19.6 (0.9) | 79.2 \pm 18.2 (0.7) | 86.5 \pm 17.8 (0.1) |
| Cognitive Functioning | 82.8 \pm 18.3 | 83.8 \pm 12.9 (0.7) | 76.8 \pm 18.4 (0.09) | 75.2 \pm 22.3 (0.04)* | 82.1 \pm 19.2 (0.9) |
| Social Functioning | 78.6 \pm 22.1 | 77.8 \pm 22.5 (0.9) | 82.3 \pm 20.8 (0.4) | 78.3 \pm 19.6 (1) | 86.8 \pm 17.8 (0.06) |
| EORTC QLQ-C30 Symptom Subscales | | | | | |
| Patients Assessed (n) | 29 | 27 | 27 | 27 | 28 |
| Fatigue | 26.3 \pm 24 | 29.3 \pm 23.9 (0.5) | 33.5 \pm 23.6 (0.1) | 30.8 \pm 20.7 (0.3) | 24.9 \pm 26.5 (0.8) |
| Nausea/ Vomiting | 12.7 \pm 20.9 | 8.1 \pm 12.9 (0.2) | 9.3 \pm 12.8 (0.3) | 8.7 \pm 10.6 (0.2) | 5.2 \pm 9.2 (0.06) |
| Pain | 9.8 \pm 16.9 | 16.3 \pm 24.3 (0.09) | 19.6 \pm 25.9 (0.03)* | 12.2 \pm 17.1 (0.6) | 20.5 \pm 26.7 (0.04)* |
| Dyspnea | 7.6 \pm 17.0 | 15.9 \pm 24.7 (0.02)* | 19.8 \pm 26.7 (0.01)* | 13.7 \pm 18.9 (0.06) | 3.6 \pm 10.5 (0.3) |
| Insomnia | 23.8 \pm 30.8 | 30.1 \pm 27.9 (0.3) | 29.7 \pm 27.2 (0.5) | 26.8 \pm 25.5 (0.7) | 27.4 \pm 29.2 (0.6) |

| | | | | | |
|------------------------|-------------|-------------------|-------------------|---------------------|--------------------|
| Appetite Loss | 18.8 ± 28.9 | 17.1 ± 23.2 (0.7) | 16.2 ± 33.8 (0.7) | 14.3 ± 24.8 (0.3) | 18.1 ± 27.6 (0.9) |
| Constipation | 10.4 ± 18.1 | 8.7 ± 22.1 (0.8) | 5.7 ± 15.1 (0.3) | 5.5 ± 12.0 (0.2) | 6.7 ± 20.2 (0.4) |
| Diarrhea | 6.6 ± 13.8 | 11.5 ± 24.4 (0.4) | 15.2 ± 23.2 (0.1) | 15.5 ± 17.2 (0.04)* | 10.1 ± 20.4 (0.4) |
| Financial Difficulties | 19.3 ± 24.3 | 15 ± 17.4 (0.2) | 13.6 ± 18.8 (0.3) | 13.4 ± 18.9 (0.1) | 10.5 ± 18.3 (0.05) |

EORTC QLQ-C30 Functional subscales are on a 0 to 100 scale with higher scores representing higher function

EORTC QLQ-C30 Symptom and mTNS subscales are on a 0 to 100 scale with higher scores representing worse symptoms

* indicates significant difference from baseline value (p<0.05)